Cord blood as a source of non-senescent lymphocytes for tumor immunotherapy

Journal of Reproductive Immunology

Volumn 85, Issue 1, 2010, Pages 47-50

  Germenis, Anastasios E ^a   Karanikas, Vaios ^a  

^a UNIVERSITY OF THESSALY   (Greece)

Author keywords

Adoptive transfer; Antitumor T cells; Immunosenescence; Replicative senescence; Umbilical cord blood

Indexed keywords

CD8 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HLA ANTIGEN; MELANOMA ANTIGEN 3; TUMOR ANTIGEN; VIRUS ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL AGING; CELL CLONE; CELL DIFFERENTIATION; DENDRITIC CELL; EFFECTOR CELL; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE; LYMPHOCYTE TRANSFER; MONONUCLEAR CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR IMMUNITY; UMBILICAL CORD BLOOD;

CELL AGING; FETAL BLOOD; HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; T-LYMPHOCYTES;

EID: 77952097313     PISSN: 01650378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jri.2010.02.002     Document Type: Article

References (37)

1. Azuma H., Yamada Y., Shibuya-Fujiwara N., Yamaguchi M., Murahashi H., Fujihara M. Functional evaluation of ex vivo expanded cord blood lymphocytes: possible use for adoptive cellular immunotherapy. Exp. Hematol. 2002, 30:346-351.
2. Ben-Porath I., Weinberg R.A. When cells get stressed: an integrative view of cellular senescence. J. Clin. Invest. 2004, 113:8-13.
3. Beziat V., Nguyen S., Lapusan S., Hervier B., Dhedin N., Bories D., et al. Fully functional NK cells after unrelated cord blood transplantation. Leukemia 2009, 23:721-728.
4. Brown J.A., Boussiotis V.A. Umbilical cord blood transplantation: basic biology and clinical challenges to immune reconstitution. Clin. Immunol. 2008, 127:286-297.
5. Cao W., Jamieson B.D., Hultin L.E., Hultin P.M., Effros R.B., Detels R. Premature aging of T cells is associated with faster HIV-1 disease progression. J. Acquir. Immune Defic. Syndr. 2009, 50:137-147.
6. Cohen Y., Nagler A. Umbilical cord blood transplantation-how, when and for whom?. Blood Rev. 2004, 18:167-179.
7. Dalle J.H., Menezes J., Wagner E., Blagdon M., Champagne J., Champagne M.A., Duval M. Characterization of cord blood natural killer cells: implications for transplantation and neonatal infections. Pediatr. Res. 2005, 57(5 Pt 1):649-655.
8. Dudley M.E., Wunderlich J.R., Yang J.C., Sherry R.M., Topalian S.L., Restifo N.P., et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 2005, 23:2346-2357.
9. Dunn G.P., Old L.J., Schreiber R.D. The three Es of cancer immunoediting. Annu. Rev. Immunol. 2004, 22:329-360.
10. + T-cell replicative senescence in human aging. Immunol. Rev. 2005, 205:147-157.
11. Eggermont A.M. Therapeutic vaccines in solid tumours: can they be harmful?. Eur. J. Cancer 2009, 45:2087-2090.
12. Hanley P.J., Cruz C.R., Savoldo B., Leen A.M., Stanojevic M., Khalil M., et al. Functionally active virus-specific T-cells that target CMV, adenovirus and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood 2009, 114:1958-1967.
13. Haynes L., Maue A.C. Effects of aging on T cell function. Curr. Opin. Immunol. 2009, 21:414-417.
14. Horowitz M.M., Gale R.P., Sondel P.M., Goldman J.M., Kersey J., Kolb H.J., et al. Graft versus-leukemia reactions after bone marrow transplantation. Blood 1990, 75:555-562.
15. Iancu E.M., Speiser D.E., Rufer N. Assessing ageing of individual T lymphocytes: mission impossible?. Mech. Ageing Dev. 2008, 129:67-78.
16. Kadereit S., Mohammad S.F., Miller R.E., Woods K.D., Listrom C.D., McKinnon K., et al. Reduced NFAT1 protein expression in human umbilical cord blood T lymphocytes. Blood 1999, 94:3101-3107.
17. Karanikas, V., Zamanakou, M., Soukou, F., Kerenidi, T., Gourgoulianis, K.I., Germenis, A.E., 2010. Frequency and function of naturally occurring cytolytic CD8+ T cell precursors against multiple tumor antigens in lung cancer patients and healthy individuals. Immunol. Cell Biol., Epub ahead of print.
18. + T cells. Cancer Res. 2006, 66:11447-11454.
19. Koch S., Solana R., Dela Rosa O., Pawelec G. Human cytomegalovirus infection and T cell immunosenescence: a mini review. Mech. Ageing Dev. 2006, 127:538-543.
20. Linton P.J., Dorshkind K. Age-related changes in lymphocyte development and function. Nat. Immunol. 2004, 5:133-139.
21. Lundqvist A., Childs R. Allogeneic hematopoietic cell transplantation as immunotherapy for solid tumors: current status and future directions. J. Immunother. 2005, 28:281-288.
22. Maue A.C., Yager E.J., Swain S.L., Woodland D.L., Blackman M.A., Haynes L. T-cell immunosenescence: lessons learned from mouse models of aging. Trends Immunol. 2009, 30:301-305.
23. Mommaas B., Stegehuis-Kamp J.A., van Halteren A.G., Kester M., Enczmann J., Wernet P., et al. Cord blood comprises antigen-experienced T cells specific for maternal minor histocompatibility antigen HA-1. Blood 2005, 105:1823-1827.
24. Mosley R.L., Koker M.M., Miller R.A. Idiosyncratic alterations of TCR size distributions affecting both CD4 and CD8 T cell subsets in aging mice. Cell Immunol. 1998, 189:10-18.
25. Nikolich-Žugich J. Ageing and life-long maintenance of T-cell subsets in the face of latent persistent infections. Nat. Rev. Immunol. 2008, 8:512-522.
26. Park K.D., Marti L., Kurtzberg J., Szabolcs P. In vitro priming and expansion of cytomegalovirus-specific Th1 and Tc1 T cells from naive cord blood lymphocytes. Blood 2006, 108:1770-1773.
27. Pawelec G., Akbar A., Caruso C., Effros R., Grubeck-Loebenstein B., Wikby A. Is immunosenescence infectious?. Trends Immunol. 2004, 25:406-410.
28. Pawelec G., Koch S., Griesemann H., Rehbein A., Hähnel K., Gouttefangeas C. Immunosenescence, suppression and tumour progression. Cancer Immunol. Immunother. 2006, 55:981-986.
29. Rosenberg S.A., Yang J.C., Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 2004, 10:909-915.
30. Solana R., Mariani E. NK and NK/T cells in human senescence. Vaccine 2000, 18:1613-1620.
31. + Epstein-Barr virus-specific cytotoxic T-lymphocytes from human umbilical cord blood. Cell Immunol. 1999, 195:81-88.
32. Tykodi S.S., Warren E.H., Thompson J.A., Riddell S.R., Childs R.W., Otterud B.E., et al. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens. Clin. Cancer Res. 2004, 10:7799-7811.
33. + donors. Eur. J. Immunol. 2005, 35:2876-2885.
34. Wang P., Munger C.M., Joshi A.D., Pirruccello S.J., Joshi S.S. Cytotoxicity of cord blood derived Her2/neu-specific cytotoxic T lymphocytes against human breast cancer in vitro and in vivo. Breast Cancer Res. Treat. 2004, 83:15-23.
35. Wikby A., Nilsson B.O., Forsey R., Thompson J., Strindhall J., Lofgren S., et al. The immune risk phenotype is associated with IL-6 in the terminal decline stage: findings from the Swedish NONA immune longitudinal study of very late life functioning. Mech. Ageing Dev. 2006, 127:695-704.
36. Yager E.J., Ahmed M., Lanzer K., Randall T.D., Woodland D.L., Blackman M.A. Age-associated decline in T cell repertoire diversity leads to holes in the repertoire and impaired immunity to influenza virus. J. Exp. Med. 2008, 205:711-723.
37. Zou W. Regulatory T cells, tumour immunity, and immunotherapy. Nat. Rev. Immunol. 2006, 6:295-307.